Migraine Drugs Market by Therapeutic Class (Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots), Treatment Type (Abortive, Preventive), Route of Administration, Distribution - Global Forecast 2024-2030

Migraine Drugs Market by Therapeutic Class (Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots), Treatment Type (Abortive, Preventive), Route of Administration, Distribution - Global Forecast 2024-2030


The Migraine Drugs Market size was estimated at USD 4.74 billion in 2023 and expected to reach USD 5.48 billion in 2024, at a CAGR 15.83% to reach USD 13.26 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Migraine Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Migraine Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Migraine Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aegis Therapeutics, LLC, Alder Biopharmaceuticals, Inc., Allergan Inc. by AbbVie Inc., Amgen, Inc., AstraZeneca Plc, Biohaven, Ltd, Eisai Co., Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Migraine Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapeutic Class

Anti-Nausea Drug
Chlorpromazine
Metoclopramide
Prochlorperazine

Blood Pressure Lowering Medication
Beta-Blocker
Calcium Channel Blocker

Ergots
Dihydroergotamines
Ergotamine
Lasmiditan

Opioid Medication
OxyContin
Percocet
Vicodin

Pain Reliever
Aspirin
Ibuprofen

Triptans
Rizatriptan
Sumatriptan
Treatment Type

Abortive

Preventive
Route of Administration

Injectable

Nasal Spray

Oral
Distribution

Hospitals Based Pharmacy

Online Pharmacy

Retail Pharmacy
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Migraine Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Migraine Drugs Market?
3. What are the technology trends and regulatory frameworks in the Migraine Drugs Market?
4. What is the market share of the leading vendors in the Migraine Drugs Market?
5. Which modes and strategic moves are suitable for entering the Migraine Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Migraine Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of migraines and launch of new drugs
5.1.1.2. Rise in female population and increase in cigarette consumption
5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
5.1.2. Restraints
5.1.2.1. Side effects associated with migraine drugs
5.1.3. Opportunities
5.1.3.1. Supportive reimbursement policies for migraine medications
5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
5.1.4. Challenges
5.1.4.1. Availability of alternative therapies and regulatory challenges
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Migraine Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Anti-Nausea Drug
6.3.1. Chlorpromazine
6.3.2. Metoclopramide
6.3.3. Prochlorperazine
6.3. Blood Pressure Lowering Medication
6.4.1. Beta-Blocker
6.4.2. Calcium Channel Blocker
6.4. Ergots
6.5.1. Dihydroergotamines
6.5.2. Ergotamine
6.5.3. Lasmiditan
6.5. Opioid Medication
6.6.1. OxyContin
6.6.2. Percocet
6.6.3. Vicodin
6.6. Pain Reliever
6.7.1. Aspirin
6.7.2. Ibuprofen
6.7. Triptans
6.8.1. Rizatriptan
6.8.2. Sumatriptan
7. Migraine Drugs Market, by Treatment Type
7.1. Introduction
7.2. Abortive
7.3. Preventive
8. Migraine Drugs Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Nasal Spray
8.4. Oral
9. Migraine Drugs Market, by Distribution
9.1. Introduction
9.2. Hospitals Based Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Migraine Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Migraine Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Migraine Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Aegis Therapeutics, LLC
14.1.3. Alder Biopharmaceuticals, Inc.
14.1.4. Allergan Inc. by AbbVie Inc.
14.1.5. Amgen, Inc.
14.1.6. AstraZeneca Plc
14.1.7. Biohaven, Ltd
14.1.8. Eisai Co., Ltd.
14.1.9. Eli Lilly and Company
14.1.10. Endo International Plc
14.1.11. GlaxoSmithKline Plc
14.1.12. H. Lundbeck A/S
14.1.13. Johnson & Johnson Services, Inc.
14.1.14. Merck & Co. Inc.
14.1.15. Pfizer Inc.
14.1.16. Sanofi SA
14.1.17. Teva Pharmaceuticals Industries Ltd
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. MIGRAINE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. MIGRAINE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MIGRAINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MIGRAINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MIGRAINE DRUGS MARKET DYNAMICS
FIGURE 7. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 8. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 10. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 14. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings